Anthony P Nunes1,2, Kristy Iglay3, Larry Radican3, Samuel S Engel3, Jing Yang1, Michael C Doherty1, David D Dore1,4. 1. Optum Epidemiology, Boston, Massachusetts. 2. Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts. 3. Merck & Co., Inc., Kenilworth, New Jersey. 4. Department of Health Services, Policy and Practice, Brown University School of Public Health, Providence, Rhode Island.
Abstract
AIMS: Certain treatments for type 2 diabetes mellitus cause hypoglycaemia and weight gain, and thus might counteract the benefits of intensive glucose control. We quantify the association of cardiovascular disease (CVD) outcomes with hypoglycaemia and weight gain among patients with type 2 diabetes treated with sulfonylureas. MATERIALS AND METHODS: This cohort study included patients from January 2009 through December 2014 who were selected from within a deidentified nationwide electronic health records repository, including multiple provider networks and electronic medical records systems. Hypoglycaemia measures from structured data fields and free text clinical notes were categorized as serious or non-serious. Covariate adjusted Poisson regression analysis was used to assess the association between frequency of hypoglycaemia (by severity), or magnitude of weight change, and incidence of acute myocardial infarction (AMI), congestive heart failure (CHF) and stroke. RESULTS: Among 143 635 eligible patients, we observed 5669 cases of AMI, 14 109 incident cases of CHF and 7017 cases of stroke. Overall incidence rates were 1.53, 4.26 and 1.92 per 100 person-years for AMI, CHF and stroke, respectively. The associations between overall hypoglycaemia and each of the CVD outcomes were positive, with stronger associations observed for serious hypoglycaemia and attenuated or null associations observed for non-serious hypoglycaemia. Weight change exhibited a U-shaped association with increased risks associated with both weight loss and weight gain relative to stable weight. CONCLUSIONS: This study provides evidence of increased CVD risk associated with hypoglycaemia, especially with serious hypoglycaemia events. While associations were attenuated with non-serious hypoglycaemia, the results were suggestive of a potential increased risk.
AIMS: Certain treatments for type 2 diabetes mellitus cause hypoglycaemia and weight gain, and thus might counteract the benefits of intensive glucose control. We quantify the association of cardiovascular disease (CVD) outcomes with hypoglycaemia and weight gain among patients with type 2 diabetes treated with sulfonylureas. MATERIALS AND METHODS: This cohort study included patients from January 2009 through December 2014 who were selected from within a deidentified nationwide electronic health records repository, including multiple provider networks and electronic medical records systems. Hypoglycaemia measures from structured data fields and free text clinical notes were categorized as serious or non-serious. Covariate adjusted Poisson regression analysis was used to assess the association between frequency of hypoglycaemia (by severity), or magnitude of weight change, and incidence of acute myocardial infarction (AMI), congestive heart failure (CHF) and stroke. RESULTS: Among 143 635 eligible patients, we observed 5669 cases of AMI, 14 109 incident cases of CHF and 7017 cases of stroke. Overall incidence rates were 1.53, 4.26 and 1.92 per 100 person-years for AMI, CHF and stroke, respectively. The associations between overall hypoglycaemia and each of the CVD outcomes were positive, with stronger associations observed for serious hypoglycaemia and attenuated or null associations observed for non-serious hypoglycaemia. Weight change exhibited a U-shaped association with increased risks associated with both weight loss and weight gain relative to stable weight. CONCLUSIONS: This study provides evidence of increased CVD risk associated with hypoglycaemia, especially with serious hypoglycaemia events. While associations were attenuated with non-serious hypoglycaemia, the results were suggestive of a potential increased risk.
Authors: Yana Anfinogenova; Elena V Grakova; Maria Shvedova; Kristina V Kopieva; Alexander T Teplyakov; Sergey V Popov Journal: Heart Fail Rev Date: 2018-05 Impact factor: 4.214
Authors: Logan Smith; Diya Chakraborty; Pallab Bhattacharya; Deepaneeta Sarmah; Sebastian Koch; Kunjan R Dave Journal: Ann N Y Acad Sci Date: 2018-06-19 Impact factor: 5.691
Authors: Judith van Dalem; Martijn C G J Brouwers; Coen D A Stehouwer; André Krings; Olaf H Klungel; Johanna H M Driessen; Frank de Vries; Andrea M Burden Journal: Diabetes Obes Metab Date: 2017-12-27 Impact factor: 6.577
Authors: Jean Strelitz; Emma R Lawlor; Yue Wu; Annabel Estlin; Giri Nandakumar; Amy L Ahern; Simon J Griffin Journal: Diabetologia Date: 2021-12-02 Impact factor: 10.122
Authors: Harold E Bays; Pam R Taub; Elizabeth Epstein; Erin D Michos; Richard A Ferraro; Alison L Bailey; Heval M Kelli; Keith C Ferdinand; Melvin R Echols; Howard Weintraub; John Bostrom; Heather M Johnson; Kara K Hoppe; Michael D Shapiro; Charles A German; Salim S Virani; Aliza Hussain; Christie M Ballantyne; Ali M Agha; Peter P Toth Journal: Am J Prev Cardiol Date: 2021-01-23
Authors: J Matthew Brennan; Martin B Leon; Paige Sheridan; Isabel J Boero; Qinyu Chen; Angela Lowenstern; Vinod Thourani; Sreekanth Vemulapalli; Kevin Thomas; Tracy Y Wang; Eric D Peterson Journal: J Am Heart Assoc Date: 2020-08-11 Impact factor: 5.501